Home Neoplasma 2017 Neoplasma Vol.64, No.4, p.605-610, 2017

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.64, No.4, p.605-610, 2017

Title: Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed
Author: O. Fiala, P. Hosek, M. Pesek, J. Finek, J. Racek, T. Buchler, A. Poprach, K. Hejduk, R. Chloupkova, O. Sorejs, M. Ecksteinova, M. Vitovec, K. Cizkova, R. Kucera, O. Topolcan

Abstract:

Pemetrexed is an intravenously administered antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). It has been previously demonstrated that the superiority of pemetrexed is limited to patients with non-squamous histology. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Clinical data of 325 patients were analysed. Serum samples were collected within one week before the initiation of treatment. The median progression-free (PFS) and overall survival (OS) for patients with high CRP was 2.1 and 9.5 compared to 4.2 and 20.5 months for those with normal CRP (p=0.002 and p<0.001, respectively).

The multivariable Cox proportional hazards model revealed that serum CRP (HR=1.46, p=0.002) was significantly associated with PFS and also with OS (HR=1.95, p<0.001). In conclusion, the study results suggest that pretreatment serum CRP is associated with poor outcome of non-squamous NSCLC patients treated with pemetrexed.



Keywords: C-reactive protein, lung cancer, NSCLC, chemotherapy, pemetrexed, prognosis
Published online: 11-Jul-2017
Year: 2017, Volume: 64, Issue: 4 Page From: 605, Page To: 610
doi:10.4149/neo_2017_416
Price: 14.40 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.